Released Nov 12, 2025, after the close
10-Q filed Nov 12, 2025, 43 days after period end · 0001390478-25-000020
Q3 2025 · 10-Q
Revenue$0.00$0.00 derivedno prior Q3 2024 on fileno prior Q2 2025 on file
Net Income-$6.79M-$6.79M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.06-$0.06 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$7,083,000N/M
Operating Cash Flowderived-$7,068,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | — | $0.00 | $0.00 |
| Net Income | -$6.79M | -$7.11M | -$9.27M | -$7.02M |
| EPS Diluted | -$0.06 | -$0.10 | -$0.33 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR